Screening Package of Hepatitis (B & C) at Chughtai Lab

Screening Package of Hepatitis (B & C) at Chughtai Lab

Hepatitis B and Hepatitis C are major global health concerns, particularly in developing countries like Pakistan, where viral hepatitis remains a significant cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (liver cancer). The Screening Package of Hepatitis (B & C) at Chughtai Lab is a specialized diagnostic blood panel designed to detect the presence of the Hepatitis B virus (HBV) and the Hepatitis C virus (HCV) in the blood. This screening package is crucial for early detection, timely medical intervention, and preventing the transmission of these potentially life-threatening viral infections. Chughtai Lab, a premier diagnostic network in Pakistan, utilizes advanced automated chemiluminescent immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) technologies to deliver highly accurate, reliable, and rapid results to patients nationwide.

Both Hepatitis B and Hepatitis C are blood-borne pathogens that target the liver, causing inflammation and progressive cellular damage. While Hepatitis B is caused by a double-stranded DNA virus (HBV) and can be prevented through vaccination, Hepatitis C is caused by an enveloped single-stranded RNA virus (HCV) for which no vaccine currently exists, though highly effective direct-acting antiviral (DAA) medications can cure it. Because both infections can remain completely asymptomatic for decades—often earning them the title of “silent killers”—routine screening is the only definitive way to identify infected individuals before irreversible liver damage occurs. The Screening Package of Hepatitis (B & C) at Chughtai Lab evaluates key serological markers, specifically the Hepatitis B Surface Antigen (HBsAg) and the Hepatitis C Antibody (Anti-HCV), providing a clear initial assessment of a patient’s viral status.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the Screening Package of Hepatitis (B & C) at Chughtai Lab is straightforward, as it is a non-invasive blood test. To ensure the most accurate results and a comfortable experience, patients should observe the following guidelines:

• Fasting Requirements: Strict fasting is generally not required for a standard Hepatitis B and C screening panel. Patients can eat and drink normally before the test. However, if other tests (such as a fasting blood sugar or lipid profile) are scheduled alongside this package, fasting for 8 to 12 hours may be necessary.
• Hydration: It is highly recommended to drink plenty of water before the blood draw. Proper hydration makes the veins more visible and accessible, facilitating a smoother venipuncture process.
• Medication Disclosure: Patients must inform the healthcare professional or phlebotomist of all prescription medications, over-the-counter drugs, vitamins, and herbal supplements they are currently taking. Some immunosuppressive drugs or recent blood transfusions can occasionally influence serological markers.
• Avoid Alcohol: It is advisable to avoid consuming alcoholic beverages for at least 24 hours prior to the test, as alcohol can temporarily stress the liver and affect concurrent liver function tests if they are being performed.
• Comfortable Clothing: Wear a short-sleeved shirt or clothing with sleeves that can be easily rolled up above the elbow to allow easy access to the venipuncture site.

During the Procedure

The blood collection process for the Screening Package of Hepatitis (B & C) at Chughtai Lab is conducted by highly trained phlebotomists adhering to strict international safety and hygiene standards. The entire procedure typically takes less than five minutes and involves the following steps:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity, confirm the requested test package, and explain the steps of the blood draw to ensure comfort and consent.
• Sanitization and Site Selection: The phlebotomist will clean the skin over the selected vein—usually located in the antecubital fossa (the inner bend of the elbow)—using an antiseptic alcohol swab. The site is allowed to air-dry completely to prevent contamination.
• Tourniquet Application: A soft elastic band (tourniquet) is tied around the upper arm to temporarily restrict blood flow, causing the veins to swell and become easier to locate and puncture.
• Venipuncture: Using a sterile, single-use, disposable needle attached to a vacuum collection tube, the phlebotomist gently inserts the needle into the vein. Patients may feel a brief, mild pinch or stinging sensation as the needle enters the skin.
• Sample Collection: Blood is drawn into a specific collection tube (typically a serum separator tube or SST with a gold or red top). Once the required volume of blood is collected, the tourniquet is released to restore normal circulation.
• Post-Draw Care: The needle is carefully withdrawn, and immediate, gentle pressure is applied to the puncture site with a sterile cotton ball or gauze pad to stop any bleeding. A small adhesive bandage is then applied over the site.
• Sample Labeling: The collection tube is immediately labeled with the patient’s unique identification details, barcode, and timestamp in the patient’s presence to prevent any risk of sample mix-up.

When is a Screening Package of Hepatitis (B & C) Performed?

Routine Health Checkups and Preventive Screening

Physicians frequently recommend the Screening Package of Hepatitis (B & C) as part of routine annual health examinations, especially for individuals living in regions with high prevalence rates of viral hepatitis. Because chronic hepatitis B and C can progress silently without causing noticeable symptoms for many years, proactive screening is the most effective clinical strategy to identify asymptomatic carriers, initiate early medical management, and prevent the silent progression of liver fibrosis, cirrhosis, and liver failure.

Pre-Employment, Pre-Surgical, and Visa Medical Requirements

This screening package is a standard requirement for pre-employment physicals, particularly for healthcare workers, food handlers, and individuals entering industries with a higher risk of occupational exposure. Additionally, major international visa processing protocols and immigration medical exams require mandatory screening for Hepatitis B and C. Surgeons also routinely request this panel before elective or major surgical procedures to protect the surgical team and implement appropriate infection control measures in the operating theater.

Evaluation of Unexplained Liver Enzyme Elevations

When routine blood tests, such as a Liver Function Test (LFT), reveal unexplained elevations in liver enzymes—specifically Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)—physicians will immediately order a Hepatitis B and C screening. Elevated ALT and AST levels indicate active hepatocellular injury or inflammation. Identifying whether this liver injury is caused by HBV or HCV infection is critical for establishing an accurate diagnosis and formulating a targeted therapeutic plan.

High-Risk Exposure and Clinical Symptoms

The screening is urgently performed when a patient presents with clinical symptoms suggestive of acute or chronic hepatitis, or after a known high-risk exposure event. Symptoms include jaundice (yellowing of the skin and eyes), dark-colored urine, pale or clay-colored stools, chronic fatigue, unexplained nausea, vomiting, abdominal pain (particularly in the upper right quadrant), and joint pain. High-risk exposures include needle-stick injuries among healthcare workers, sharing of needles or personal care items like razors, undergoing blood transfusions or medical procedures in unregulated facilities, and unprotected sexual contact with an infected individual.

Prenatal Screening for Pregnant Women

Obstetricians routinely prescribe the Screening Package of Hepatitis (B & C) during early prenatal care for all pregnant women. Vertical transmission from mother to child during childbirth is a primary route of Hepatitis B transmission. Identifying a mother’s HBV status allows healthcare providers to administer the Hepatitis B vaccine and Hepatitis B Immune Globulin (HBIG) to the newborn within the first 12 hours of birth, preventing chronic infection in the infant. Screening for Hepatitis C during pregnancy is also essential for managing maternal health and planning postpartum care.

What Does a Screening Package of Hepatitis (B & C) Detect?

The Screening Package of Hepatitis (B & C) at Chughtai Lab is designed to detect specific serological markers and clinical indicators associated with viral hepatitis infections. The primary findings and clinical detections include:

• Presence of Hepatitis B Surface Antigen (HBsAg): This is the primary diagnostic marker for detecting active Hepatitis B infection. A positive or reactive HBsAg result indicates that the patient is currently infected with HBV, either as an acute or chronic infection, and can transmit the virus to others.
• Absence of Hepatitis B Surface Antigen (HBsAg): A negative or non-reactive HBsAg result indicates that there is no active Hepatitis B infection detected at the time of testing.
• Presence of Hepatitis C Antibodies (Anti-HCV): This marker detects the presence of antibodies produced by the body’s immune system in response to a Hepatitis C virus infection. A reactive result indicates exposure to HCV at some point in the patient’s life.
• Absence of Hepatitis C Antibodies (Anti-HCV): A non-reactive result indicates that no antibodies to the Hepatitis C virus were detected, suggesting no prior or current exposure to the virus.
• Acute Hepatitis B Infection: Detected when HBsAg is positive in a patient presenting with acute clinical symptoms of liver inflammation.
• Chronic Hepatitis B Infection: Suggested when HBsAg remains positive in the blood for longer than six months, indicating a persistent, long-term viral infection.
• Prior Exposure to Hepatitis C: A reactive Anti-HCV test indicates that the patient has been exposed to the Hepatitis C virus, which could represent an active chronic infection or a past infection that has cleared spontaneously or been successfully treated.
• Need for Confirmatory PCR Testing: If the Anti-HCV screen is reactive, it detects the clinical necessity for a qualitative or quantitative HCV RNA Polymerase Chain Reaction (PCR) test to confirm whether an active, replicating viral infection is present.
• Need for HBV DNA PCR Testing: A reactive HBsAg screen identifies the clinical requirement for an HBV DNA PCR test to measure the viral load and assess the rate of viral replication.
• Co-infection Status: The package can detect simultaneous infections of both Hepatitis B and Hepatitis C, which is a critical clinical finding as co-infection significantly accelerates the progression of liver disease.
• Asymptomatic Carrier State: Detects active viral infections in individuals who show absolutely no physical symptoms of liver disease, allowing for early monitoring and lifestyle modifications.
• Potential Risk of Vertical Transmission: Identifies pregnant women who are HBsAg-positive, highlighting the immediate clinical need for neonatal immunoprophylaxis at birth.
• Screening Clearance for Blood Donation: Confirms whether a donor’s blood is safe and free from HBV and HCV, preventing transfusion-transmitted infections.
• Screening Clearance for Organ Transplantation: Evaluates the viral status of potential organ donors and recipients to prevent post-transplant viral reactivation or transmission.
• Occupational Health Assessment: Determines the viral status of healthcare workers following accidental needle-stick or mucosal exposure to potentially infectious blood or body fluids.
• Indication for Hepatitis B Vaccination: A non-reactive HBsAg result in an individual with no immunity indicates that the patient is a candidate for the highly effective Hepatitis B vaccine series.
• Need for Gastroenterology or Hepatology Referral: A reactive result for either marker detects the clinical necessity for a specialist consultation to evaluate liver health, perform staging (such as FibroScan), and discuss antiviral therapy.
• Potential Risk of Liver Cirrhosis: Early detection of chronic HBV or HCV helps identify patients at risk of developing progressive liver scarring (cirrhosis) if left untreated.
• Potential Risk of Hepatocellular Carcinoma (HCC): Identifying chronic viral hepatitis allows clinicians to enroll patients in regular ultrasound and Alpha-Fetoprotein (AFP) surveillance programs for early detection of liver cancer.
• Screening Clearance for Immunosuppressive Therapy: Detects HBV status prior to starting chemotherapy, biological therapies, or immunosuppressive drugs, preventing potentially fatal reactivation of latent Hepatitis B.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is highly regarded for its state-of-the-art laboratory automation and efficient reporting systems, ensuring that patients receive their diagnostic results promptly. The turnaround time (TAT) for the Screening Package of Hepatitis (B & C) is typically within 12 to 24 hours from the time of sample collection. This rapid processing is essential for reducing patient anxiety and allowing physicians to make timely clinical decisions, especially in pre-surgical or urgent exposure scenarios.

Patients can access their diagnostic reports easily through multiple convenient digital channels provided by Chughtai Healthcare. Once the laboratory pathologists verify and sign off on the results, an automated SMS notification containing a secure, direct download link is sent to the patient’s registered mobile number. Reports can also be viewed, downloaded, and printed directly from the official Chughtai Lab website by entering the patient’s case number and access code. Additionally, the Chughtai Healthcare mobile application, available on both iOS and Android platforms, offers a centralized portal where patients can view their complete diagnostic history, track report status, and share PDF reports directly with their consulting physicians. For those who prefer physical copies, printed reports can be collected from any Chughtai Lab diagnostic center or collection point across Pakistan.

Screening Package of Hepatitis (B & C) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Hepatitis B Surface Antigen (HBsAg)	Non-Reactive (Negative)	Reactive (Positive) – Indicates active Hepatitis B infection (acute or chronic).
Hepatitis C Antibody (Anti-HCV)	Non-Reactive (Negative)	Reactive (Positive) – Indicates exposure to Hepatitis C; requires confirmatory PCR testing.
Liver Enzymes (ALT/AST)*	Within normal reference ranges (typically < 40-50 U/L)	Elevated levels indicating active liver inflammation or hepatocellular injury.
Total Bilirubin*	Within normal reference range (0.2 – 1.2 mg/dL)	Elevated levels (hyperbilirubinemia) indicating impaired liver clearance or biliary obstruction.
Viral Replication Status	No viral replication detected	Active viral replication (confirmed via HBV DNA or HCV RNA PCR testing).
Immune Status (HBV)	Protected (if Anti-HBs is positive)	Susceptible to infection (if HBsAg, Anti-HBs, and Anti-HBc are all negative).
Clinical Interpretation	No serological evidence of active HBV or HCV infection.	Active, chronic, or resolved viral hepatitis requiring specialist clinical evaluation.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Screening Package of Hepatitis (B & C)?

• Experienced Healthcare Professionals: Chughtai Lab’s pathology department is led by highly qualified, board-certified pathologists, microbiologists, and experienced laboratory technologists who ensure the highest standards of diagnostic accuracy.
• Patient-Focused Care: The laboratory prioritizes patient comfort, safety, and confidentiality, providing a supportive and professional environment at every collection center.
• Quality Diagnostic Services: Chughtai Lab participates in rigorous internal and external quality assurance programs, adhering to international standards of laboratory medicine.
• Professional Reporting: Reports are detailed, clear, and structured to provide actionable clinical insights for both patients and their treating physicians.
• Modern Diagnostic Approach: The laboratory utilizes state-of-the-art, fully automated immunoassay analyzers and molecular diagnostic platforms to minimize human error and deliver precise results.
• Comfortable Environment: All diagnostic centers and collection points are designed to offer a clean, hygienic, and welcoming environment for patients of all ages.
• Convenient Location: With an extensive network of hundreds of collection centers across Pakistan, patients can easily find a Chughtai Lab facility near their home or workplace.
• Commitment to Accurate Diagnosis: Chughtai Lab is dedicated to providing reliable, evidence-based diagnostic services, helping in the early detection and effective management of viral hepatitis nationwide.